Proactive Research analyst Emma Ulker discusses MaxCyte's (LON:MXCT) commercial momentum across its cell therapy business, which led to 21% year-on-year top-line growth to US $26.2mln in fiscal (FY) 2020.
Ulker says this included three new strategic licences with high profile cell therapy developers, a fourth signed post period, a rise in recurring revenues from instrument leases and disposable sales in cell therapy, accelerated by the receipt of milestone payments from partners.